4 transcripts
REGN
Earnings call transcript
NASDAQ
2024 Q2
1 Aug 24
.
Beyond COPD later this year, we are looking forward to data readouts from Phase III studies of DUPIXENT in chronic spontaneous urticaria and bullous
REGN
Earnings call transcript
NASDAQ
2024 Q1
2 May 24
continue to position EYLEA HD as the new standard of care for retinal diseases.
Shifting to chronic obstructive pulmonary disease or COPD where Regeneron
REGN
Earnings call transcript
NASDAQ
2023 Q4
2 Feb 24
prescription share in the United States across all 5 of its approved indications.
We also had a major breakthrough in chronic obstructive pulmonary
REGN
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
in patients with wet AMD.
Moving to our immunology and inflammation pipeline on Dupixent. We look forward to the FDA decision for our sBLA in chronic
- Prev
- 1
- Next